Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer

Lung, Respiratory and Thoracic CancerSkin Cancer

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

JAMA Oncol.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B

doi: 10.1001/

Lung, Respiratory and Thoracic Cancer

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

JAMA Oncol.

Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J

doi: 10.1001/jamaoncol.2020.5012.

Lung, Respiratory and Thoracic Cancer

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

JAMA Oncol.

Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ

doi: 10.1001/jamaoncol.2020.4232.

Central Nervous System TumorsLung, Respiratory and Thoracic Cancer

An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer

Eur J Cancer.

Tsakonas G, Lewensohn R, Botling J, Ortiz-Villalon C, Micke P, Friesland S, Nord H, Lindskog M, Sandelin M, Hydbring P, Ekman S

doi: 10.1016/j.ejca.2020.03.014.

Lung, Respiratory and Thoracic Cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

J Clin Oncol.

Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M

doi: 10.1200/JCO.19.02674.

Radio-Oncology

Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017

J Thorac Oncol.

Donington JS, Kim YT, Tong B, Moreira AL, Bessich J, Weiss KD, Colson YL, Wigle D, Osarogiagbon RU, Zweig J, Wakelee H, Blasberg J, Daly M, Backhus L, Van Schil P

doi: 10.1016/j.jtho.2018.04.002.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Lung, Respiratory and Thoracic Cancer

Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer

Lung Cancer

Baine MJ, Verma V, Schonewolf CA, Lin C, Simone II CB

doi: 10.1016/

Lung, Respiratory and Thoracic Cancer

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer

JAMA Oncol.

Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM

doi: 10.1001/jamaoncol.2019.1747.

Related content

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features

An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer